Cheng Xin / Getty Images
Shares of DexCom (DXCM) jumped more than 15% to pace the S&P 500’s advancers Friday, a day after the maker of glucose monitoring devices for people with diabetes reported better-than-expected quarterly revenue and announced a $750 million stock buyback program.
DexCom, which is based in San Diego reported that its first-quarter revenues grew 12% on an annual basis to $1.04 Billion. Visible Alpha’s analysts surveyed expected $1.02 billion. The adjusted earnings per share of 32c missed estimates by one penny.
DexCom has confirmed its full-year forecast for revenue of $4.6 Billion, adjusted operating margins of approximately 21% and adjusted EBITDA Margin of about 30%.
It has lowered its projections for 2025 of the adjusted gross profit margin at approximately 62% due to “incremental costs relating to near-term demand dynamics.”
Friday's surge moved shares of DexCom into positive territory for 2025. At around $81, they're still a bit off Visible Alpha's average analyst price target, which is currently a bit above $98.
